2m 2m 2m 2m 2m 2m 2m
- $29.3MMarket Cap
- -33.10%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
ROCKWELL MEDICAL (RMTI)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 19
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
Rockwell Medical Tops Q2 EPS View
Rockwell Medical reported Q2 2025 earnings with a 37.8% revenue decline due to losing its largest customer, but signed four new multi-year supply agreements and maintained tight cost controls.
08/14/2025, 6:21 AM • The Motley Fool
Peers
Statistics
MoreInformation as of 06/03/2026
Company Profile
Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. It offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, bicarbonate cartridges, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. In addition, it offers dialysis concentrates, dialysis kits, and other ancillary products used in the dialysis process. The company was formerly known as Rockwell Medical Technologies, Inc. and changed its name to Rockwell Medical, Inc. in June 2012. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
Key Executives
- Mark Strobeck
- Megan C. Timmins
- Jesse Neri
- Nicholas Fanslau
- Timothy T. Chole
Current Ownership Distribution
- Institutions94.9M (58.06%)
- Mutual Funds56.2M (34.41%)
- Insiders12.3M (7.53%)
- Other0 (0.00%)